130 related articles for article (PubMed ID: 35778608)
1. Azithromycin does not increase hematologic relapse in pediatric hematopoietic cell transplant recipients.
Sabulski A; Wallace G; Lane A; Davies SM; Myers KC
Bone Marrow Transplant; 2022 Oct; 57(10):1589-1591. PubMed ID: 35778608
[No Abstract] [Full Text] [Related]
2. Azithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients.
Sheshadri A; Saliba R; Patel B; Ahmed T; Bueno LC; Arain MH; Mehta RS; Popat UR; Hosing CM; Rondon G; Bashoura L; Dickey BF; Champlin RE; Alousi AM
Bone Marrow Transplant; 2021 Mar; 56(3):745-748. PubMed ID: 33009515
[No Abstract] [Full Text] [Related]
3. Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial.
Bergeron A; Chevret S; Granata A; Chevallier P; Vincent L; Huynh A; Tabrizi R; Labussiere-Wallet H; Bernard M; Chantepie S; Bay JO; Thiebaut-Bertrand A; Thepot S; Contentin N; Fornecker LM; Maillard N; Risso K; Berceanu A; Blaise D; Peffault de La Tour R; Chien JW; Coiteux V; Socié G;
JAMA; 2017 Aug; 318(6):557-566. PubMed ID: 28787506
[TBL] [Abstract][Full Text] [Related]
4. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction.
Wayne AS; Giralt S; Kröger N; Bishop MR
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1534-6. PubMed ID: 24035783
[TBL] [Abstract][Full Text] [Related]
5. Palliative care of hematopoietic cell transplant recipients and families.
Tierney DK; Passaglia J; Jenkins P
Semin Oncol Nurs; 2014 Nov; 30(4):253-61. PubMed ID: 25361877
[TBL] [Abstract][Full Text] [Related]
6. Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor.
Tang FF; Cheng YF; Xu LP; Zhang XH; Yan CH; Han W; Chen YH; Huang XJ; Wang Y
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1655-1662. PubMed ID: 32504861
[TBL] [Abstract][Full Text] [Related]
7. Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation.
Vallet N; Le Grand S; Bondeelle L; Hoareau B; Corneau A; Bouteiller D; Tournier S; Derivry L; Bohineust A; Tourret M; Gibert D; Mayeur E; Itzykson R; Pacchiardi K; Ingram B; Cassonnet S; Lepage P; Peffault de Latour R; Socié G; Bergeron A; Michonneau D
Blood; 2022 Dec; 140(23):2500-2513. PubMed ID: 35984904
[TBL] [Abstract][Full Text] [Related]
8. Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG.
Othman J; Greenwood M; Moore J; Larsen S; Watson AM; Arthur C; Bhattacharyya A; Bilmon I; Blyth E; Bryant A; Bryant C; Dunlop L; Fay K; Gibson J; Hamad N; Kerridge I; Kwan J; Ma D; Micklethwaite K; Milliken S; Panicker S; Stevenson W; Withers B; Wilcox L; Tran S; Gottlieb DJ
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1868-1875. PubMed ID: 32640314
[TBL] [Abstract][Full Text] [Related]
9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
Devine SM; Sanborn R; Jessop E; Stock W; Huml M; Peace D; Wickrema A; Yassine M; Amin K; Thomason D; Chen YH; Devine H; Maningo M; van Besien K
Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768
[TBL] [Abstract][Full Text] [Related]
11. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
van Besien K; Hari P; Zhang MJ; Liu HT; Stock W; Godley L; Odenike O; Larson R; Bishop M; Wickrema A; Gergis U; Mayer S; Shore T; Tsai S; Rhodes J; Cushing MM; Korman S; Artz A
Haematologica; 2016 May; 101(5):634-43. PubMed ID: 26869630
[TBL] [Abstract][Full Text] [Related]
12. Immune Reconstitution Following TCRαβ/CD19-Depleted Hematopoietic Cell Transplantation for Hematologic Malignancy in Pediatric Patients.
Arnold DE; MacMath D; Seif AE; Heimall JR; Wang Y; Monos D; Grupp SA; Bunin NJ
Transplant Cell Ther; 2021 Feb; 27(2):169.e1-169.e9. PubMed ID: 33830028
[TBL] [Abstract][Full Text] [Related]
13. Circulating T cell profiles associate with enterotype signatures underlying hematological malignancy relapses.
Vallet N; Salmona M; Malet-Villemagne J; Bredel M; Bondeelle L; Tournier S; Mercier-Delarue S; Cassonnet S; Ingram B; Peffault de Latour R; Bergeron A; Socié G; Le Goff J; Lepage P; Michonneau D
Cell Host Microbe; 2023 Aug; 31(8):1386-1403.e6. PubMed ID: 37463582
[TBL] [Abstract][Full Text] [Related]
14. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant.
Shaw BE; Mufti GJ; Mackinnon S; Cavenagh JD; Pearce RM; Towlson KE; Apperley JF; Chakraverty R; Craddock CF; Kazmi MA; Littlewood TJ; Milligan DW; Pagliuca A; Thomson KJ; Marks DI; Russell NH
Bone Marrow Transplant; 2008 Dec; 42(12):783-9. PubMed ID: 18724393
[TBL] [Abstract][Full Text] [Related]
15. Second allogeneic hematopoietic cell transplantation for relapse after first allografts.
Gyurkocza B; Storb R; Chauncey TR; Maloney DG; Storer BE; Sandmaier BM
Leuk Lymphoma; 2019 Jul; 60(7):1758-1766. PubMed ID: 30668198
[TBL] [Abstract][Full Text] [Related]
16. Mononuclear Cell Telomere Attrition Is Associated with Overall Survival after Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies.
Helby J; Petersen SL; Kornblit B; Nordestgaard BG; Mortensen BK; Bojesen SE; Sengeløv H
Biol Blood Marrow Transplant; 2019 Mar; 25(3):496-504. PubMed ID: 30266676
[TBL] [Abstract][Full Text] [Related]
17. Improving allogeneic stem cell transplantation in myelofibrosis.
Gagelmann N; Kröger N
Int J Hematol; 2022 May; 115(5):619-625. PubMed ID: 35419771
[TBL] [Abstract][Full Text] [Related]
18. [Single center comparative analysis of hematopoietic cell transplantation from alternated donor in patients with hematologic malignancies].
Wang J; Zhou J; Zheng HF; Wang PF; Fu CC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Feb; 23(1):159-65. PubMed ID: 25687066
[TBL] [Abstract][Full Text] [Related]
19. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.
Naik S; Martinez C; Leung K; Sasa G; Nguyen NY; Wu MF; Gottschalk S; Brenner M; Heslop H; Krance R
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1266-72. PubMed ID: 25765555
[TBL] [Abstract][Full Text] [Related]
20. [Effect of BU and CY versus TBI and CY as conditioning regimens on the efficacy of haploidentical stem cell transplantation in patients with hematologic malignancy].
Shao Q; Han D; Liu D; Zheng X; Dong L; Wang Z; Ding L; Yan H; Wang H; Duan L
Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):505-10. PubMed ID: 24985173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
